Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Timothy E. Hoffman"'
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
BRAF inhibitors are used to treat late-stage melanoma patients harbouring BRAF mutations. Here the authors track the responses of single melanoma cells to BRAF inhibitors and show that a subset of cells rapidly escapes drug via non-genetic mechanisms
Externí odkaz:
https://doaj.org/article/6a13f959447645ecb054fba975625421
Publikováno v:
Frontiers in Molecular Biosciences, Vol 7 (2020)
Alzheimer’s disease (AD) is the leading cause of dementia and one of the most common causes of death worldwide. As an age-dependent multifactorial disease, the causative triggers of AD are rooted in spontaneous declines in cellular function and met
Externí odkaz:
https://doaj.org/article/3cc2ed1eee3244478905563c69f3d296
Publikováno v:
bioRxiv
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway and many targeted inhibitors now exist for clinical use, but drug resistance remains a major issue. We recently showed that BRAF-driven melanoma ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ab42bc85da173967f1f2fb71a4ff2c6
https://doi.org/10.1101/2023.03.17.533211
https://doi.org/10.1101/2023.03.17.533211
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Nature Communications
Nature Communications
Despite the increasing number of effective anti-cancer therapies, successful treatment is limited by the development of drug resistance. While the contribution of genetic factors to drug resistance is undeniable, little is known about how drug-sensit
Publikováno v:
Cancer Research. 83:3865-3865
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway and many targeted inhibitors now exist for clinical use, but drug resistance remains a major issue. We previously showed that BRAF-driven melanoma
Autor:
Mansi Arora, Justin Moser, Timothy E. Hoffman, Lotte P. Watts, Mingwei Min, Monica Musteanu, Yao Rong, Jordan Schneider, C Ryland Ill, Varuna Nangia, Manuel Sanclemente, John Lapek, Lisa Nguyen, Sherry Niessen, Stephen Dann, Todd van Arsdale, Mariano Barbacid, Nichol Miller, Sabrina L. Spencer
Publikováno v:
Cancer Research. 83:5992-5992
CDK2 is a core cell-cycle enzyme that phosphorylates a variety of substrates to drive progression through the cell cycle. CDK2 is hyperactivated in multiple cancers and is therefore an attractive therapeutic target. Here, application of a novel small
Autor:
Laura J. Macdougall, Timothy E. Hoffman, Bruce E. Kirkpatrick, Benjamin D. Fairbanks, Christopher N. Bowman, Sabrina L. Spencer, Kristi S. Anseth
Publikováno v:
Advanced Materials. 34:2202882
To survive extreme conditions, certain animals enter a reversible protective stasis through vitrification of the cytosol by polymeric molecules such as proteins and polysaccharides. In this work, synthetic gelation of the cytosol in living cells is u
Publikováno v:
Aging Cell
Summary Research in biogerontology has largely focused on the complex relationship between mitochondrial dysfunction and biological aging. In particular, the mitochondrial free radical theory of aging (MFRTA) has been well accepted. However, this the
Publikováno v:
Computational Toxicology. 3:19-32
Benzoic acid (BA) is a common preservative used in food and beverage products. In this study, we systematically reviewed the available pharmacokinetic data for BA within a variety of animal models to design multiple species-specific physiologically-b
Autor:
Lyle E. Wallis, Kasimir F. Carranza, Timothy E. Hoffman, Vincenzo S. Gilberto, Evan R. Acerbo, William H. Hanneman
Publikováno v:
Archives of toxicology. 93(3)
The aryl hydrocarbon receptor (AhR) is a nuclear receptor that facilitates a wide transcriptional response and causes a variety of adaptive and maladaptive physiological functions. Such functions are entirely dependent on the type of ligand activatin